Bell Bank cut its stake in Johnson & Johnson (NYSE:JNJ) by 32.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,405 shares of the company’s stock after selling 1,160 shares during the period. Bell Bank’s holdings in Johnson & Johnson were worth $358,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of JNJ. Nordea Investment Management AB grew its holdings in Johnson & Johnson by 88.0% in the 2nd quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after buying an additional 8,062,204 shares in the last quarter. BlackRock Inc. boosted its position in Johnson & Johnson by 0.6% during the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after acquiring an additional 1,168,129 shares during the period. MUFG Securities EMEA plc grew its stake in shares of Johnson & Johnson by 124.7% in the second quarter. MUFG Securities EMEA plc now owns 1,506,456 shares of the company’s stock worth $211,853,000 after purchasing an additional 836,139 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in shares of Johnson & Johnson by 290.9% during the second quarter. Handelsbanken Fonder AB now owns 1,114,004 shares of the company’s stock valued at $156,662,000 after purchasing an additional 829,053 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its stake in shares of Johnson & Johnson by 37.7% during the second quarter. DekaBank Deutsche Girozentrale now owns 1,635,829 shares of the company’s stock valued at $228,237,000 after purchasing an additional 447,991 shares in the last quarter. Institutional investors own 67.44% of the company’s stock.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.27% of the stock is owned by corporate insiders.
JNJ has been the subject of a number of recent analyst reports. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $161.00 to $164.00 in a research report on Monday, July 20th. Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Credit Suisse Group boosted their target price on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a report on Wednesday, October 14th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Bank of America reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson currently has an average rating of “Buy” and a consensus price target of $164.93.
JNJ stock opened at $150.85 on Tuesday. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The firm has a market capitalization of $397.12 billion, a PE ratio of 23.72, a P/E/G ratio of 3.04 and a beta of 0.69. The firm has a 50-day moving average of $145.39 and a two-hundred day moving average of $146.58.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. During the same quarter in the previous year, the business earned $2.12 earnings per share. The firm’s revenue was up 1.7% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.68%. The ex-dividend date of this dividend is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: Retained Earnings
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).